Method of achieving persistent transgene expression

Details for Australian Patent Application No. 2004240187 (hide)

Owner Novartis AG

Inventors Mina, Mervat; Ennist, David Leonard; Lu, Patrick

Agent Davies Collison Cave

Pub. Number AU-A-2004240187

Parent 31648

Filing date 17 December 2004

Wipo publication date 20 January 2005

International Classifications

C12N 015/86 Mutation or genetic engineering - Viral vectors

A61P 037/00 Drugs for immunological or allergic disorders

A61P 019/02 Drugs for skeletal disorders

A61K 048/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

Event Publications

6 January 2005 Complete Application Filed

20 January 2005 Application Open to Public Inspection

  Published as AU-A-2004240187

19 June 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004240188-Building and using subwebs for focused search

2004240186-Device for local administration of solid or semi-solid formulations and delayedrelease formulations for parenteral administration and preparation process